LT2411053T - Stabilus geležies oligosacharido junginys - Google Patents

Stabilus geležies oligosacharido junginys

Info

Publication number
LT2411053T
LT2411053T LTEP09776213.2T LT09776213T LT2411053T LT 2411053 T LT2411053 T LT 2411053T LT 09776213 T LT09776213 T LT 09776213T LT 2411053 T LT2411053 T LT 2411053T
Authority
LT
Lithuania
Prior art keywords
oligosaccharide compound
stable iron
iron oligosaccharide
stable
compound
Prior art date
Application number
LTEP09776213.2T
Other languages
English (en)
Inventor
Hans Andreasen
Original Assignee
Pharmacosmos Holding A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41350678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2411053(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacosmos Holding A/S filed Critical Pharmacosmos Holding A/S
Publication of LT2411053T publication Critical patent/LT2411053T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP09776213.2T 2009-03-25 2009-03-25 Stabilus geležies oligosacharido junginys LT2411053T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/DK2009/050069 WO2010108493A1 (en) 2009-03-25 2009-03-25 A stable iron oligosaccharide compound

Publications (1)

Publication Number Publication Date
LT2411053T true LT2411053T (lt) 2017-04-10

Family

ID=41350678

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP16201189.4T LT3156075T (lt) 2009-03-25 2009-03-25 Oligosacharidas ir jo paruošimo būdas
LTEP09776213.2T LT2411053T (lt) 2009-03-25 2009-03-25 Stabilus geležies oligosacharido junginys

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP16201189.4T LT3156075T (lt) 2009-03-25 2009-03-25 Oligosacharidas ir jo paruošimo būdas

Country Status (26)

Country Link
US (7) US8815301B2 (lt)
EP (3) EP3821910A1 (lt)
JP (1) JP5426010B2 (lt)
KR (1) KR101580348B1 (lt)
CN (3) CN109700828A (lt)
AU (1) AU2009342799B2 (lt)
BR (1) BRPI0924653B8 (lt)
CA (1) CA2756580A1 (lt)
CY (2) CY1118725T1 (lt)
DK (2) DK2411053T3 (lt)
EA (1) EA023917B1 (lt)
ES (2) ES2617658T3 (lt)
HK (1) HK1164138A1 (lt)
HR (2) HRP20170230T1 (lt)
HU (2) HUE052617T2 (lt)
LT (2) LT3156075T (lt)
MX (1) MX2011009936A (lt)
NZ (1) NZ595597A (lt)
PH (1) PH12015500891A1 (lt)
PL (2) PL2411053T3 (lt)
PT (2) PT3156075T (lt)
RS (2) RS61104B1 (lt)
SI (2) SI2411053T1 (lt)
UA (1) UA103373C2 (lt)
WO (1) WO2010108493A1 (lt)
ZA (1) ZA201107431B (lt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101905340B1 (ko) 2006-01-06 2018-10-05 루이트폴드 파머수티컬스, 인코퍼레이티드 철을 투여하기 위한 방법 및 조성물
CN109700828A (zh) 2009-03-25 2019-05-03 法码科思莫斯控股有限公司 稳定的铁寡糖复合物
CN103626807B (zh) * 2013-11-20 2017-07-07 青岛国风药业股份有限公司 一种多糖铁复合物的制备方法及其质量检测方法
CZ2014451A3 (cs) * 2014-06-30 2016-01-13 Contipro Pharma A.S. Protinádorová kompozice na bázi kyseliny hyaluronové a anorganických nanočástic, způsob její přípravy a použití
RS59240B1 (sr) * 2014-10-27 2019-10-31 Pharmacosmos Holding As Lečenje ili prevencija anemije kod gravidnih sisara koji nisu ljudi i njihovih potomaka
WO2016206699A1 (en) 2015-06-22 2016-12-29 Pharmacosmos Holding A/S Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant
US10258647B2 (en) 2015-09-01 2019-04-16 Particle Dynamics International, Llc Iron-polysaccharide complexes and methods for the preparation thereof
CA2932075C (en) * 2015-09-01 2020-11-17 Particle Dynamics International, Llc Iron-polysaccharide complexes and methods for the preparation thereof
CN105908611A (zh) * 2016-06-12 2016-08-31 天津康远工程机械有限公司 具有清洗功能的自动找平双层预应力烫平板
EP3450443A1 (en) 2017-08-29 2019-03-06 Jennewein Biotechnologie GmbH Process for purifying sialylated oligosaccharides
AU2018328052B2 (en) 2017-09-11 2024-02-29 Pharmacosmos Holding A/S Iron complex compounds for therapeutic use
CN109646454A (zh) * 2018-12-29 2019-04-19 博瑞生物医药（苏州）股份有限公司 异麦芽糖酐铁1000的制备方法
SG11202107050RA (en) 2019-01-10 2021-07-29 Pharmacosmos Holding As Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation
CN114286682A (zh) 2019-02-09 2022-04-05 法码科思莫斯控股有限公司 治疗具有心血管不良事件风险的个体的铁缺乏以及用于治疗心房颤动的铁
US11447513B2 (en) * 2020-02-12 2022-09-20 Rk Pharma Inc. Purification process of ferric carboxymaltose
CN118019542A (zh) 2021-08-03 2024-05-10 法码科思莫斯控股有限公司 用于在治疗伴侣动物缺铁中皮下使用的铁络合化合物
WO2024069644A1 (en) * 2022-09-30 2024-04-04 West Bengal Chemical Industries Limited A pharmaceutically acceptable ferric carboxymaltose and preparation thereof
CN116672360B (zh) * 2023-06-30 2024-05-14 重庆汉佩生物科技有限公司 一种妥曲珠利与葡庚糖酐铁的组合物
CN116726045B (zh) * 2023-06-30 2024-03-19 重庆汉佩生物科技有限公司 一种氟雷拉纳组合物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA623412A (en) 1961-07-04 Muller Arthur Iron polyisomaltose complexes for therapeutical application
CA623411A (en) 1961-07-04 Muller Arthur Process for the manufacture of iron-polyisomaltose complex for therapeutical purposes
US2807610A (en) * 1952-02-15 1957-09-24 Baker Chem Co J T Hydrogenated dextran
US3100202A (en) 1960-06-17 1963-08-06 Muller Arthur Process for preparing an iron hydroxide polyisomaltose complex and the resulting product
US3076798A (en) 1961-02-23 1963-02-05 Hausmann Lab Ltd Process for preparing a ferric hydroxide polymaltose complex
DE1293144B (de) 1964-11-04 1969-04-24 Hausmann Ag Labor Verfahren zur Herstellung von Komplexverbindungen des Eisens mit Sorbit, Gluconsaeure und einem Oligosaccharid
US3639588A (en) 1966-10-22 1972-02-01 Fisons Pharmaceuticals Ltd Pharmaceutical compositions containing ferric hydroxide complexed with dextran or dextrin heptonic acids
GB1594697A (en) * 1977-04-19 1981-08-05 Pharmacia Ab Oligosaccharide compositions for parenteral use
DE3026868C2 (de) 1980-07-16 1986-03-13 Laboratorien Hausmann AG, St. Gallen Verfahren zur Herstellung von Eisen(III)hydroxid-Dextran-Komplexen und sie enthaltende pharmazeutische sterile wäßrige Lösung
US4518581A (en) * 1981-11-02 1985-05-21 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Imparting low- or anti-cariogenic property to orally-usable products
DE3422249A1 (de) 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Wasserloesliches eisendextran und verfahren zu seiner herstellung
US5624668A (en) 1995-09-29 1997-04-29 Luitpold Pharmaceuticals, Inc. Iron dextran formulations
US6219440B1 (en) 1997-01-17 2001-04-17 The University Of Connecticut Method and apparatus for modeling cellular structure and function
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
DK173138B1 (da) 1998-11-20 2000-02-07 Pharmacosmos Holding As Fremgangsmåde til fremstilling af en jerndextranforbindelse, jerndextranforbindelse fremstillet efter fremgangsmåden, farma
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
WO2000061191A2 (en) 1999-04-09 2000-10-19 Advanced Magnetics, Inc. Heat stable coated colloidal iron oxides
KR20020096284A (ko) * 2001-06-19 2002-12-31 현대자동차주식회사 자동차의 연료 누유 진단장치
PT1492821E (pt) * 2002-04-09 2006-12-29 Pharmacosmos Holding As Compostos de ferro-dextrina para o tratamento de anemia por deficiência de ferro
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US20060116349A1 (en) 2003-03-14 2006-06-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
US6960571B2 (en) 2003-03-14 2005-11-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
US7964568B2 (en) * 2003-05-30 2011-06-21 Chromaceutical Advanced Technologies, Inc. Synthesis of high molecular weight iron-saccharidic complexes
CN101155593A (zh) * 2005-02-09 2008-04-02 维福（国际）股份公司 铁（ⅲ）络合物化合物的应用
ITMO20050056A1 (it) 2005-03-15 2006-09-16 Biofer Spa Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi.
CN100528237C (zh) * 2005-04-26 2009-08-19 重庆医药工业研究院有限责任公司 多核的氢氧化铁-糖复合物的制备方法
EP1757299A1 (de) 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
KR101905340B1 (ko) 2006-01-06 2018-10-05 루이트폴드 파머수티컬스, 인코퍼레이티드 철을 투여하기 위한 방법 및 조성물
EP1997833A1 (de) 2007-05-29 2008-12-03 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydratderivat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
CN109700828A (zh) 2009-03-25 2019-05-03 法码科思莫斯控股有限公司 稳定的铁寡糖复合物
EP2877848A4 (en) 2012-07-27 2016-03-23 Intrinsic Life Sciences Llc METHOD FOR TREATING FERMENTED ANEMIA
CA2889855A1 (en) 2012-11-01 2014-05-08 Robert S. Katz Methods for treating fibromyalgia
CN104918486B (zh) 2012-11-30 2017-12-15 法玛科思莫斯股份公司 冷冻保护试剂,冷冻保护和冷冻保存的组合物,其用途,和冷冻保存方法

Also Published As

Publication number Publication date
PL3156075T3 (pl) 2021-04-19
WO2010108493A1 (en) 2010-09-30
EP3156075A1 (en) 2017-04-19
CN102361651A (zh) 2012-02-22
CY1118725T1 (el) 2017-07-12
EP3156075B1 (en) 2020-10-14
ES2840074T3 (es) 2021-07-06
US9439969B2 (en) 2016-09-13
NZ595597A (en) 2013-05-31
EA201190214A1 (ru) 2012-04-30
US10414831B2 (en) 2019-09-17
JP5426010B2 (ja) 2014-02-26
EP2411053B1 (en) 2016-11-30
EP3821910A1 (en) 2021-05-19
HRP20170230T1 (hr) 2017-04-07
US8815301B2 (en) 2014-08-26
UA103373C2 (ru) 2013-10-10
ES2617658T3 (es) 2017-06-19
US20120010166A1 (en) 2012-01-12
LT3156075T (lt) 2021-01-11
US20140364598A1 (en) 2014-12-11
PT2411053T (pt) 2017-02-15
SI3156075T1 (sl) 2021-03-31
BRPI0924653B1 (pt) 2019-10-08
MX2011009936A (es) 2011-10-06
US20210108004A1 (en) 2021-04-15
DK3156075T3 (da) 2020-11-30
CN109700828A (zh) 2019-05-03
HUE052617T2 (hu) 2021-05-28
EA023917B1 (ru) 2016-07-29
US10865255B2 (en) 2020-12-15
US20140303364A1 (en) 2014-10-09
EP2411053A1 (en) 2012-02-01
DK2411053T3 (en) 2017-02-20
KR20120016063A (ko) 2012-02-22
CA2756580A1 (en) 2010-09-30
US11851504B2 (en) 2023-12-26
PT3156075T (pt) 2021-01-05
ZA201107431B (en) 2012-07-25
CN108752395A (zh) 2018-11-06
PL2411053T3 (pl) 2017-06-30
JP2012521369A (ja) 2012-09-13
BRPI0924653B8 (pt) 2021-05-25
KR101580348B1 (ko) 2016-01-04
AU2009342799A1 (en) 2011-11-03
HRP20201903T1 (hr) 2021-01-22
RS55700B1 (sr) 2017-07-31
HK1164138A1 (zh) 2012-09-21
AU2009342799B2 (en) 2014-12-18
PH12015500891B1 (en) 2016-11-14
SI2411053T1 (sl) 2017-04-26
US20190135947A1 (en) 2019-05-09
US20160333118A1 (en) 2016-11-17
BRPI0924653A2 (pt) 2016-01-26
RS61104B1 (sr) 2020-12-31
CY1123651T1 (el) 2022-03-24
PH12015500891A1 (en) 2016-11-14
US20210130505A1 (en) 2021-05-06
HUE030866T2 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
HRP20170230T1 (hr) Stabilan spoj željezo oligosaharida
EP2423182A4 (en) DIACYLETHYLENEDIAMINE COMPOUND
GB0808840D0 (en) A compound structure
GB0903759D0 (en) Compound
EP2393493A4 (en) LINKS
EP2491025A4 (en) AZA-AZULENE COMPOUNDS
GB0914767D0 (en) Compound
EP2505585A4 (en) BIS benzoxazinone CONNECTION
EP2428106A4 (en) CABINET
GB0909213D0 (en) Compound
IL215235A0 (en) Pyrazole compound
IL214028A0 (en) A novel cyanopyrimidine derivative
GB0914883D0 (en) Compound
EP2487178A4 (en) PYRAZOLOTHIAZOLVERBINDUNG
EP2443115A4 (en) COMPOUNDS
GB201001904D0 (en) A structure
EP2502926A4 (en) COMPOUND
GB2475691B (en) A mounting arrangement
GB0901976D0 (en) Compound
GB0917460D0 (en) Compound
GB0922003D0 (en) Compound
GB0906821D0 (en) Compound
GB0910692D0 (en) Compound
GB0916603D0 (en) Compound
GB0922714D0 (en) Compound